Maravai LifeSciences Holdings Inc. [NASDAQ: MRVI] closed the trading session at $38.18 on 07/07/21. The day’s price range saw the stock hit a low of $37.18, while the highest price level was $39.99. The company report on May 27, 2021 that Maravai LifeSciences Announces June 2021 Investor Conference Schedule.
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of June.
On June 1, 2021, Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the William Blair Annual Growth Stock Conference at 10:00 a.m. PT.
The stocks have a year to date performance of 36.11 percent and weekly performance of -10.77 percent. The stock has been moved at 41.41 percent over the last six months. The stock has performed -8.20 percent around the most recent 30 days and changed 17.62 percent over the most recent 3-months.
If compared to the average trading volume of 1.42M shares, MRVI reached to a volume of 1713891 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Maravai LifeSciences Holdings Inc. [MRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $50.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Maravai LifeSciences Holdings Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 16, 2020. The new note on the price target was released on December 15, 2020, representing the official price target for Maravai LifeSciences Holdings Inc. stock. Previously, the target price had yet another raise to $31, while Stifel analysts kept a Buy rating on MRVI stock.
The Average True Range (ATR) for Maravai LifeSciences Holdings Inc. is set at 1.79, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 26.28. The Price to Book ratio for the last quarter was 32.63, with the Price to Cash per share for the same quarter was set at 0.94.
MRVI stock trade performance evaluation
Maravai LifeSciences Holdings Inc. [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.77. With this latest performance, MRVI shares dropped by -8.20% in over the last four-week period, additionally plugging by 41.41% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 35.51, with the RSI for the last a single of trading hit 25.85, and the three-weeks RSI is set at 41.90 for Maravai LifeSciences Holdings Inc. [MRVI]. The present Moving Average for the last 50 days of trading for this stock 39.93, while it was recorded at 39.76 for the last single week of trading.
Maravai LifeSciences Holdings Inc. [MRVI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Maravai LifeSciences Holdings Inc. [MRVI] shares currently have an operating margin of +35.52 and a Gross Margin at +69.29. Maravai LifeSciences Holdings Inc.’s Net Margin is presently recorded at +27.06.
Return on Total Capital for MRVI is now 15.76, given the latest momentum, and Return on Invested Capital for the company is 12.79. Return on Equity for this stock inclined to 66.89, with Return on Assets sitting at 8.32. When it comes to the capital structure of this company, Maravai LifeSciences Holdings Inc. [MRVI] has a Total Debt to Total Equity ratio set at 667.47. Additionally, MRVI Total Debt to Total Capital is recorded at 86.97, with Total Debt to Total Assets ending up at 46.49. Long-Term Debt to Equity for the company is recorded at 660.69, with the Long-Term Debt to Total Capital now at 86.09.
Reflecting on the efficiency of the workforce at the company, Maravai LifeSciences Holdings Inc. [MRVI] managed to generate an average of $187,532 per employee. Receivables Turnover for the company is 8.11 with a Total Asset Turnover recorded at a value of 0.31.Maravai LifeSciences Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.60.
Earnings per share (EPS) analysis for Maravai LifeSciences Holdings Inc. [MRVI] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRVI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Maravai LifeSciences Holdings Inc. go to -4.00%.
Maravai LifeSciences Holdings Inc. [MRVI]: Insider Ownership positions
There are presently around $3,758 million, or 89.70% of MRVI stock, in the hands of institutional investors. The top three institutional holders of MRVI stocks are: GTCR LLC with ownership of 27,646,515, which is approximately 0% of the company’s market cap and around 0.21% of the total institutional ownership; FMR LLC, holding 9,703,243 shares of the stock with an approximate value of $370.47 million in MRVI stocks shares; and MASSACHUSETTS FINANCIAL SERVICES CO /MA/, currently with $205.53 million in MRVI stock with ownership of nearly 27.062% of the company’s market capitalization.
Positions in Maravai LifeSciences Holdings Inc. stocks held by institutional investors increased at the end of September and at the time of the September reporting period, where 96 institutional holders increased their position in Maravai LifeSciences Holdings Inc. [NASDAQ:MRVI] by around 21,559,073 shares. Additionally, 62 investors decreased positions by around 20,490,662 shares, while 13 investors held positions by with 56,385,440 shares. The mentioned changes placed institutional holdings at 98,435,175 shares, according to the latest SEC report filing. MRVI stock had 57 new institutional investments in for a total of 4,871,146 shares, while 29 institutional investors sold positions of 12,869,185 shares during the same period.